The central studies published in 2017 address novel IBD therapeutic strategies and prediction of the future disease course or response to a distinct therapy. Together, these studies contribute to the understanding of the regulation of mucosal homeostasis and at the same time serve to develop novel personalized treatment algorithms in patients in whom a severe disease course can be predicted.
This is a preview of subscription content, log in via an institution to check access.
References
Franke, A. et al. Genome-wide meta-analysis increases to 71 the number of confirmed Crohn's disease susceptibility loci. Nat. Genet. 42, 1118–1125 (2010).
Paramsothy, S. et al. Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389, 1218–1228 (2017).
Siegmund, B. Is intensity the solution for FMT in ulcerative colitis? Lancet 389, 1170–1172 (2017).
Feagan, B. G. et al. Ustekinumab as induction and maintenance therapy for Crohn's Disease. N. Engl. J. Med. 375, 1946–1960 (2016).
Feagan, B. G. et al. Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study. Lancet 389, 1699–1709 (2017).
Sands, B. E. et al. Efficacy and safety of MEDI2070, an antibody against interleukin 23, in patients with moderate to severe Crohn's disease: a phase 2a study. Gastroenterology 153, 77–86.e6 (2017).
West, N. R. et al. Oncostatin M drives intestinal inflammation and predicts response to tumor necrosis factor-neutralizing therapy in patients with inflammatory bowel disease. Nat. Med. 23, 579–589 (2017).
Atreya, R. et al. In vivo imaging using fluorescent antibodies to tumor necrosis factor predicts therapeutic response in Crohn's disease. Nat. Med. 20, 313–318 (2014).
Lee, J. C. et al. Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn's disease. Nat. Genet. 49, 262–268 (2017).
Plomin, R., Haworth, C. M. & Davis, O. S. Common disorders are quantitative traits. Nat. Rev. Genet. 10, 872–878 (2009).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
R.A. served as consultant for Abbvie, Janssen and Pfizer, and received speaker's fees from Abbvie, Falk, Janssen, MSD and Takeda. B.S. received a research grant from Pfizer, served as consultant for Falk, Janssen, MSD, Abbvie, Takeda and Hospira, and received lecture fees from Abbvie, Falk, Ferring, MSD, Merck and Takeda; all money went to the Charité–Universitätsmedizin Berlin, Germany.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Atreya, R., Siegmund, B. Development of therapy for and prediction of IBD — getting personal. Nat Rev Gastroenterol Hepatol 15, 72–74 (2018). https://doi.org/10.1038/nrgastro.2017.166
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrgastro.2017.166
- Springer Nature Limited